CPT1A and hepatocellular carcinoma: Next, we treated STAM mice with LPL/FABP4/CPT1 small-molecule inhibitors, including Orlistat, BMS309403 and Etomoxir, to determine whether the interference of this metabolic axis affects the occurrence of HCC.